No abstract available
MeSH terms
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Clinical Trials, Phase II as Topic
-
Depsipeptides*
-
Heart / drug effects
-
Humans
-
Hypertension / chemically induced
-
Neutropenia / chemically induced
-
Oligopeptides / administration & dosage*
-
Oligopeptides / adverse effects
-
Oligopeptides / pharmacology
-
Structure-Activity Relationship
Substances
-
Antineoplastic Agents
-
Depsipeptides
-
Oligopeptides
-
dolastatin 15
-
cemadotin
-
dolastatin 10